John E. Bishop - 27 Feb 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Technology Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact for John E. Bishop
Issuer symbol
LYRA
Transactions as of
27 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 15:10:19 UTC
Previous filing
14 Oct 2022
Next filing
01 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +220,000 $0.000000 220,000 27 Feb 2023 Common Stock 220,000 $2.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable as to 25% of the underlying shares on February 27, 2024 and in 36 substantially equal monthly installments thereafter.